Iressa Increases the Sensitivity of NPC Cell Lines to Taxol
نویسندگان
چکیده
منابع مشابه
TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines
Microtubules are cellular targets for a variety of anticancer therapies because of their critical function in mitosis. Taxol belongs to a class of microtubule targeting agents that suppresses microtubule dynamics and interferes with the functioning of the mitotic spindle, thereby effectively blocking cell cycle progression of rapidly proliferating tumor cells. Despite its antitumor activity, dr...
متن کاملPancreatic Cancer Cell Lines Activation and Sensitivity to Gefitinib (Iressa) in Human Constitutive Epidermal Growth Factor Receptor Pathway
The epidermal growth factor receptor (EGFR) is considered an important therapeutic target in pancreatic cancer, but it is currently impossible to identify those patients who are most likely to benefit from EGFR-directed therapy. We examined the biological effects of the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in a panel of nine human pancreatic cancer cell lines. The drug stro...
متن کاملCharacterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines.
Paclitaxel (Taxol), a cytotoxic natural product that disrupts microtubule integrity, is being clinically evaluated for use against gliomas. We examined paclitaxel-induced killing in seven cell lines derived from human malignant astrocytic gliomas and medulloblastomas with the goal of characterizing range of sensitivity, contribution of P-glycoprotein 170-mediated drug efflux to resistance, and ...
متن کاملRNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in approximately 30% of acute myelogenous leukemia (AML) patients and appears to confer an adverse prognosis. Thus, development of inhibitors and/or antibodies that specifically target FLT3 has been of substantial interest. In this regard, phase 1 and 2 trials involving FLT3 inhibitors have recently...
متن کاملPrediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor receptor-tyrosine kinase, has shown potent anti-tumor effects and improved symptoms and quality-of-life of a subset of patients with advanced non-small cell lung cancer (NSCLC). However, a large portion of the patients showed no effect to this agent. To establish a method to predict the response of NSCLC patients to gefitinib, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Otolaryngology–Head and Neck Surgery
سال: 2010
ISSN: 0194-5998,1097-6817
DOI: 10.1016/j.otohns.2010.06.348